Journal article icon

Journal article

High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia

Abstract:

In acute myeloid leukemia (AML), risk stratification based on cytogenetics and mutation profiling is essential but remains insufficient to select the optimal therapy. Accurate biomarkers are needed to improve prognostic assessment. We analyzed RNA sequencing and survival data of 430 AML patients and identified HMGA2 as a novel prognostic marker. We validated a quantitative PCR test to study the association of HMGA2 expression with clinical outcomes in 358 AML samples. In this training cohort,...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1038/s41408-018-0103-6

Authors


More by this author
Role:
Author
ORCID:
0000-0001-9095-0066
Expand authors...
Genome Canada More from this funder
Génome Québec More from this funder
Canada Research Chair More from this funder
University of Montreal More from this funder
Fonds de recherche du Québec More from this funder
Expand funders...
Publisher:
Nature Publishing Group Publisher's website
Journal:
Blood Cancer Journal Journal website
Volume:
8
Issue:
8
Pages:
68
Publication date:
2018-07-19
Acceptance date:
2018-06-01
DOI:
EISSN:
2044-5385
ISSN:
2044-5385
Pubs id:
pubs:905015
URN:
uri:98a1db73-1d6f-4c1c-968e-3c07a44d77f8
UUID:
uuid:98a1db73-1d6f-4c1c-968e-3c07a44d77f8
Local pid:
pubs:905015
Language:
English
Keywords:

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP